Objective: Although percutaneous transluminal angioplasty is an effective therapy against vascular access failure in hemodialysis patients, recurrent stenosis imposes enormous burden for hemodialysis patients. A nitinol scoring elementequipped helical balloon catheter (AngioSculpt ® ) has been altered the landscape for treating several vascular diseases. It is not, however, fully elucidated whether AngioSculpt for advanced vascular access stenosis, difficult to expand by conventional balloons, successfully provides bailout angioplasty. Here, we report our cases whose intradialytic venous pressure significantly improved after percutaneous transluminal angioplasty without any serious adverse complications using AngioSculpt. Patients and Methods: Among patients undergoing hemodialysis in Masuko Memorial Hospital, 16 cases with resistant and recurrent vascular access stenosis underwent AngioSculpt (diameter 6 mm, total length 4 cm) angioplasty. We simultaneously measured the average venous pressures during hemodialysis before and after percutaneous transluminal angioplasty. Results: The average outflow vessel stenosis rate was 73.0 ± 11.3% before AngioSculpt intervention. Fully enlarged vessels were observed by expanding vessels at maximum pressure of 14 atm in all cases without any complications including vascular ruptures. Their intradialytic venous pressures decreased from 181.8 ± 39.2 mmHg to 150.5 ± 39.3 mmHg (p < 0.0001). Conclusion: AngioSculpt may provide a promising option for treating hemodialysis patients with severely advanced vascular access stenosis, who would otherwise need repeated vascular access surgeries and/or conventional percutaneous transluminal angioplasties.
Introduction
Percutaneous transluminal angioplasty (PTA) is an effective treatment against blood flow disturbance in hemodialysis vascular access. Recurrent vascular access stenosis, however, still imposes enormous burden for hemodialysis patients.
AngioSculpt ® PTA Scoring Balloon Catheter (Philips, Japan, Inc.) was developed as an effective device for patients with advanced stenotic lesions in which conventional PTA balloons are unable to achieve favorable patency because of their insufficient expansion. AngioSculpt significantly has altered the landscape for treating vascular disease since its first appearance.
A case series of favorable vessel dilatation using a nitinol scoring element-equipped helical balloon catheter (AngioSculpt ® )
This revolutionary innovated balloon catheter produces a "cutting" effect called "scoring" during balloon dilation by attaching a spirally shaped nitinol wire on the surface of semi-compliant balloon (Figure 1) . The "scoring" effect is expected to lock the device in place and reduce balloon slippage and is unlikely to cause excessive vascular damage or vascular dissection ( Figure 2 ). [1] [2] [3] [4] Several efficacies for coronary and limb arteries have been reported in recent years. [4] [5] [6] [7] It is not, however, fully elucidated how AngioSculpt for advanced stenotic lesions successfully provides bailout angioplasty.
Here, we report our cases whose vessel patency was well maintained by PTA using AngioSculpt without any serious adverse complications.
Patients and methods
Of all the 121 patients in whom PTA was enforced in Masuko Memorial Hospital between August and November 2017, we examined retrospectively 16 cases with resistant and recurrent vascular access stenosis using AngioSculpt (balloon diameter and length, 6 mm and 4 cm, respectively) PTA procedure. All of them who had need repeated PTAs within 3 months previously.
We collected data of meticulously calculated patency rate from digital subtraction angiography (Philips, Tokyo, Japan) analyses before and after balloon expansion. We also simultaneously measured the average venous pressures during hemodialysis before and after PTA.
Results
Patient profiles and characteristics are shown in Table 1 . Their mean age was 69.8 ± 13.3 years, their average hemodialysis history was 113.3 ± 119.5 months, and they all needed repeated PTAs (6.4 ± 2.4 times) because of The mechanism of dilatation by AngioSculpt. As the balloon expands, the radial forces are concentrated along the surfaces of the nitinol element and provide "scoring" marks, which are expected to lock the device in place and reduce balloon slippage. recurrent vessel restenosis. They all underwent PTAs using AngioSculpt, aiming for larger vessel dilatations. Fully enlarged vessels were observed by expanding vessels at maximum pressure of 14 atm in all cases without any complications including vascular ruptures. This nitinol-wired balloon expansion significantly decreased stenosis rate, and those enlarged outflow vessels significantly reduced intradialytic venous pressures (Figure 3) , accomplishing stable hemodialysis sessions afterward in all cases.
Discussion
Our study has demonstrated that AngioSculpt in PTA is feasible and safe for the treatment for advanced vascular access stenosis. Balloon angioplasty using AngioSculpt provides a significant enlargement regarding vascular access stenosis rate and intradialytic venous pressure reduction. This nitinol-anchoring helical balloon angioplasty technique has its own clinical relevance because intradialytic venous pressure decrease ensures patients to undergo stable hemodialysis, although moderate stenosis remains after balloon dilation according to our results.
AngioSculpt was released as an effective device for advanced stenotic lesions. Bosiers M et al. 7 demonstrate that PTA using AngioSculpt has good primary patency rate in severe infrapopliteal disease. However, there is a lack of evidence comparing AngioSculpt with conventional balloons, leaving the scoring PTA catheter behind current guidelines.
NSE Alpha ® , designed for precise dilatation across a wide range of lesion types, is another scoring balloon catheter aiming to control scoring the vessel wall and reduce slippage during inflation. Utilizing the other unique catheter may deliver comparable results, according to our results. The critical limitation of this study is a lack of data about stenosis rates and vessel diameters using conventional balloon catheters, well before the scoring balloon intervention.
AngioSculpt may provide a promising option for treating hemodialysis patients with severely advanced vascular access stenosis that would otherwise need repeated vascular access surgeries and/or conventional PTAs.
We would also like to emphasize additionally that this evolutionary innovated balloon catheter brings about less patients' pain and stress during PTA procedures. More patients, a longer follow-up, and randomized trials comparing AngioSculpt with conventional other devices are eagerly awaited.
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